154 related articles for article (PubMed ID: 33518616)
1. Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy.
Fujiwara Y; Ohmoto A; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Yuasa T; Yonese J; Takahashi S
Endocr J; 2021 Jun; 68(6):671-681. PubMed ID: 33518616
[TBL] [Abstract][Full Text] [Related]
2. Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas.
Asai S; Katabami T; Tsuiki M; Tanaka Y; Naruse M
Horm Cancer; 2017 Apr; 8(2):108-118. PubMed ID: 28108930
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma.
Tanabe A; Naruse M; Nomura K; Tsuiki M; Tsumagari A; Ichihara A
Horm Cancer; 2013 Apr; 4(2):103-10. PubMed ID: 23361939
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.
Niemeijer ND; Alblas G; van Hulsteijn LT; Dekkers OM; Corssmit EP
Clin Endocrinol (Oxf); 2014 Nov; 81(5):642-51. PubMed ID: 25041164
[TBL] [Abstract][Full Text] [Related]
5. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.
Huang H; Abraham J; Hung E; Averbuch S; Merino M; Steinberg SM; Pacak K; Fojo T
Cancer; 2008 Oct; 113(8):2020-8. PubMed ID: 18780317
[TBL] [Abstract][Full Text] [Related]
6. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
7. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.
Hadoux J; Terroir M; Leboulleux S; Deschamps F; Al Ghuzlan A; Hescot S; Tselikas L; Borget I; Caramella C; Déandréis D; Goere D; De Baere T; Schlumberger M; Baudin E
Horm Cancer; 2017 Dec; 8(5-6):330-337. PubMed ID: 28748315
[TBL] [Abstract][Full Text] [Related]
9. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.
Ilanchezhian M; Jha A; Pacak K; Del Rivero J
Curr Treat Options Oncol; 2020 Aug; 21(11):85. PubMed ID: 32862332
[TBL] [Abstract][Full Text] [Related]
10. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience.
Shilkrut M; Bar-Deroma R; Bar-Sela G; Berniger A; Kuten A
Am J Clin Oncol; 2010 Feb; 33(1):79-82. PubMed ID: 19704370
[TBL] [Abstract][Full Text] [Related]
11. Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature.
Deutschbein T; Fassnacht M; Weismann D; Reincke M; Mann K; Petersenn S
Clin Endocrinol (Oxf); 2015 Jan; 82(1):84-90. PubMed ID: 25143180
[TBL] [Abstract][Full Text] [Related]
12. [A case of metastatic pheochromocytoma with remarkable response to combination of cyclophosphamide, vincristine and dacarbazine].
Naoi Y; Tamaki Y; Ooka M; Tsukamoto F; Miyoshi Y; Tanji Y; Taguchi T; Noguchi S
Gan To Kagaku Ryoho; 2003 Jan; 30(1):145-9. PubMed ID: 12557721
[TBL] [Abstract][Full Text] [Related]
13. Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy.
Jawed I; Velarde M; Därr R; Wolf KI; Adams K; Venkatesan AM; Balasubramaniam S; Poruchynsky MS; Reynolds JC; Pacak K; Fojo T
Cell Mol Neurobiol; 2018 Jul; 38(5):1099-1106. PubMed ID: 29623478
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.
Ayala-Ramirez M; Feng L; Habra MA; Rich T; Dickson PV; Perrier N; Phan A; Waguespack S; Patel S; Jimenez C
Cancer; 2012 Jun; 118(11):2804-12. PubMed ID: 22006217
[TBL] [Abstract][Full Text] [Related]
15. Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy.
Nomura K; Kimura H; Shimizu S; Kodama H; Okamoto T; Obara T; Takano K
J Clin Endocrinol Metab; 2009 Aug; 94(8):2850-6. PubMed ID: 19470630
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan.
Naruse M; Satoh F; Tanabe A; Okamoto T; Ichihara A; Tsuiki M; Katabami T; Nomura M; Tanaka T; Matsuda T; Imai T; Yamada M; Harada T; Kawata N; Takekoshi K
Endocr J; 2018 Mar; 65(3):359-371. PubMed ID: 29353821
[TBL] [Abstract][Full Text] [Related]
19. Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?
Ellis RJ; Patel D; Prodanov T; Sadowski S; Nilubol N; Adams K; Steinberg SM; Pacak K; Kebebew E
J Am Coll Surg; 2013 Sep; 217(3):489-96. PubMed ID: 23891076
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol.
Kobayakawa M; Shiga T; Takahashi K; Sugawara S; Nomura K; Hanada K; Ishizuka N; Ito H
PLoS One; 2024; 19(5):e0303623. PubMed ID: 38805424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
